Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Immuno-Biological Laboratories Co (TSE:4570) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Immuno-Biological Laboratories Co's EV-to-EBIT for today is
Immuno-Biological Laboratories Co's current Enterprise Value is 円8,585 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Immuno-Biological Laboratories Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was 円302 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Immuno-Biological Laboratories Co's EV-to-EBITDA for today is:
Immuno-Biological Laboratories Co's current Enterprise Value is 円8,585 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Immuno-Biological Laboratories Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was 円320 Mil.
Immuno-Biological Laboratories Co's current Enterprise Value is 円8,585 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Immuno-Biological Laboratories Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was 円1,005 Mil.
Immuno-Biological Laboratories Co's current Enterprise Value is 円8,585 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Immuno-Biological Laboratories Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was 円301 Mil.
Immuno-Biological Laboratories Co's current Enterprise Value is 円8,585 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Immuno-Biological Laboratories Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was 円268 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immuno-Biological Laboratories Co Enterprise Value Related Terms
Immuno-Biological Laboratories Co Enterprise Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immuno-Biological Laboratories Co Enterprise Value Chart
TSE:4570 vs VRTX, REGN, ALNY: Enterprise Value Comparison
For the Biotechnology subindustry, Immuno-Biological Laboratories Co's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immuno-Biological Laboratories Co Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immuno-Biological Laboratories Co's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Immuno-Biological Laboratories Co's Enterprise Value falls into.
Immuno-Biological Laboratories Co Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immuno-Biological Laboratories Co (TSE:4570) has a Enterprise Value of 円8,585 Mil as of Jul. 04, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Immuno-Biological Laboratories Co and its competitors.
Is Immuno-Biological Laboratories Co's Enterprise Value too high?
Immuno-Biological Laboratories Co's current Enterprise Value is 円8,585 Mil. Overall, Immuno-Biological Laboratories Co has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Immuno-Biological Laboratories Co's Enterprise Value compare to VRTX and REGN?
Immuno-Biological Laboratories Co's Enterprise Value of 円8,585 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Immuno-Biological Laboratories Co and its competitors. Immuno-Biological Laboratories Co's current Enterprise Value is 円8,585 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immuno-Biological Laboratories Co stock overvalued right now?
Based on GuruFocus' analysis, Immuno-Biological Laboratories Co (TSE:4570) is currently considered Significantly Overvalued. The stock's GF Value™ is 円577.54, compared to a current price of 円1,009.00 — trading 74.7% above its estimated fair value. The current Enterprise Value is 円8,585 Mil. Immuno-Biological Laboratories Co's overall GF Score™ is 58/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Immuno-Biological Laboratories Co (TSE:4570), the current Enterprise Value is 円8,585 Mil as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Immuno-Biological Laboratories Co (TSE:4570) Overvalued in 2026?
Based on GuruFocus' analysis, Immuno-Biological Laboratories Co stock appears to be overvalued.
The current stock price of 円1,009.00 is trading 74.7% above its estimated GF Value™ of 円577.54.
GuruFocus considers Immuno-Biological Laboratories Co to be Significantly Overvalued.
Key valuation signals for TSE:4570:
Enterprise Value: 円8,585 Mil
GF Value™: 円577.54 vs. price of 円1,009.00 (74.7% above fair value)
No single metric tells the full story. See the TSE:4570 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Immuno-Biological Laboratories Co Business Description
Immuno-Biological Laboratories Co Ltd focuses on research and development. It researches, develops, manufacture and supplies various immunological research reagents, and customized services. It is engaged in research and development of materials used in diagnostic products and valuable seeds and technology for protein production using transgenic silkworm cocoons, which make it possible to create valuable proteins as well as antibodies. It works on clinical reagents for cancer research. Its research scientists are producing inflammatory cytokines, growth factors & antibodies for use against these cancers.
58GF Score
Get the complete analysis for TSE:4570
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4570 has been successfully added to your 
